IL6 and hepatocellular carcinoma: The IL-6/JAK/STAT3 pathway has been shown to polarize macrophages toward the pro-tumoral M2 phenotype through activation of STAT3, and anti-IL-6 immunotherapy increased the number of M1 polarized macrophages in a hepatocellular carcinoma mouse model (40).